Download PDF
Nuklearmedizin 2010; 49(05): N41-N43
DOI: 10.1055/s-0038-1626515
Case report
Schattauer GmbH

Advanced inoperable type B3 thymoma: Monitoring of a novel therapeutic approach with radio-chemo therapy and sorafenib by FDG-PET and CT

T. Winder
1   Department of Medicine, Academic Teaching Hospital Feldkirch, Austria
2   Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
7   Private University in the Principality of Liechtenstein
,
A. Schuster
3   Department of Radiology, Academic Teaching Hospital Feldkirch, Austria
,
A. Becherer
4   Department of Nuclear Medicine, Academic Teaching Hospital Feldkirch, Austria
,
K. Gasser
1   Department of Medicine, Academic Teaching Hospital Feldkirch, Austria
2   Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
7   Private University in the Principality of Liechtenstein
,
A. De Vries
5   Department of Radiotherapy, Academic Teaching Hospital Feldkirch, Austria
,
U. Gruber-Moesenbacher
6   Department of Pathology, Academic Teaching Hospital Feldkirch, Austria
,
A. Muendlein
2   Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
7   Private University in the Principality of Liechtenstein
,
H. Drexel
1   Department of Medicine, Academic Teaching Hospital Feldkirch, Austria
2   Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
7   Private University in the Principality of Liechtenstein
8   Drexel University College of Medicine, Philadelphia, PA, USA
,
A. Lang
1   Department of Medicine, Academic Teaching Hospital Feldkirch, Austria
2   Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
› Author Affiliations
Further Information

Publication History

Received: 29 March 2010

accepted in revised form: 21 May 2010

Publication Date:
25 January 2018 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Antoch G, Kanja J, Bauer S. et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-365.
    PubMedGoogle Scholar
  • 2 Blumberg D, Burt ME, Bains MS. et al. Thymic carcinoma: current staging does not predict prognosis. J Thorac Cardiovasc Surg 1998; 115: 303-309.
    CrossrefPubMedGoogle Scholar
  • 3 Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg 2004; 77: 1860-1869.
    CrossrefPubMedGoogle Scholar
  • 4 Endo M, Nakagawa K, Ohde Y. et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008; 61: 350-355.
    CrossrefPubMedGoogle Scholar
  • 5 Fornasiero A, Daniele O, Ghiotto C. et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8: 1419-1423.
    CrossrefPubMedGoogle Scholar
  • 6 Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003; 125: 434-436.
    CrossrefPubMedGoogle Scholar
  • 7 Hejna M, Haberl I, Raderer M. et al. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871-1884.
    CrossrefPubMedGoogle Scholar
  • 8 Jeong YJ, Lee KS, Kim J. et al. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis?. AJR Am J Roentgenol 2004; 183: 283-289.
    CrossrefPubMedGoogle Scholar
  • 9 Khosravi Shahi P, Fernandez Pineda I. Tumoral angiogenesis: review of the literature. Cancer Invest 2008; 26: 104-108.
    CrossrefPubMedGoogle Scholar
  • 10 Masaoka A, Monden Y, Nakahara K. et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492.
    CrossrefPubMedGoogle Scholar
  • 11 Molhoek KR, Griesemann H, Shu J. et al. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008; 68: 4392-4397.
    CrossrefPubMedGoogle Scholar
  • 12 Ogawa K, Toita T, Uno T. et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002; 94: 3115-3119.
    CrossrefPubMedGoogle Scholar
  • 13 Prior JO, Montemurro M, Orcurto MV. et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009; 27: 439-445.
    CrossrefPubMedGoogle Scholar
  • 14 Rea F, Marulli G, Girardi R. et al. Long-term survival and prognostic factors in thymic epithelial tumours. Eur J Cardiothorac Surg 2004; 26: 412-418.
    CrossrefPubMedGoogle Scholar
  • 15 Sadohara J, Fujimoto K, Muller NL. et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol 2006; 60: 70-79.
    CrossrefPubMedGoogle Scholar
  • 16 Stroobants S, Goeminne J, Seegers M. et al. 18FDG- Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-2020.
    CrossrefPubMedGoogle Scholar
  • 17 Sung YM, Lee KS, Kim BT. et al. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006; 47: 1628-1634.
    PubMedGoogle Scholar
  • 18 Tomita M, Matsuzaki Y, Edagawa M. et al. Correlation between tumor angiogenesis and invasive- ness in thymic epithelial tumors. J Thorac Cardio- vasc Surg 2003; 124: 493-498.
    Google Scholar
  • 19 Travis WD, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classification of tumours. IARC Press 2004; 145-197.
    Google Scholar
  • 20 Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38 Suppl 5 S60-S65.
    PubMedGoogle Scholar
  • 21 Wilhelm SM, Adnane L, Newell P. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor ty- rosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
    CrossrefPubMedGoogle Scholar
  • 22 Wilhelm SM, Carter C, Tang L. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
    CrossrefPubMedGoogle Scholar